BriaCell Therapeutics Corp.
BCTX
$4.45
$0.143.25%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.61M | 1.76M | 1.56M | 1.63M | 1.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.53M | 8.32M | 8.55M | 6.33M | 7.17M |
| Operating Income | -7.53M | -8.32M | -8.55M | -6.33M | -7.17M |
| Income Before Tax | -7.30M | -8.28M | -8.16M | -6.22M | -6.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.30M | -8.28M | -8.16M | -6.22M | -6.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 75.10K | 80.80K | 72.70K | 98.00K | 46.40K |
| Net Income | -7.22M | -8.20M | -8.09M | -6.13M | -6.29M |
| EBIT | -7.53M | -8.32M | -8.55M | -6.33M | -7.17M |
| EBITDA | -7.50M | -8.30M | -8.53M | -6.30M | -7.14M |
| EPS Basic | -2.58 | -4.35 | -9.23 | -16.40 | -23.31 |
| Normalized Basic EPS | -1.60 | -2.73 | -5.78 | -10.15 | -14.50 |
| EPS Diluted | -2.58 | -4.35 | -9.24 | -16.40 | -23.31 |
| Normalized Diluted EPS | -1.60 | -2.73 | -5.78 | -10.15 | -14.50 |
| Average Basic Shares Outstanding | 2.80M | 1.88M | 877.10K | 373.60K | 270.00K |
| Average Diluted Shares Outstanding | 2.80M | 1.88M | 877.10K | 373.60K | 270.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |